CAMBRIDGE, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013 at 10:00 a.m. (ET) at the Grand Hyatt in New York, New York. A live webcast of Merrimack's presentation can be accessed by visiting the Investors section of the company's website at investors.merrimackpharma.com. A replay of the webcast will be archived on Merrimack's website for two weeks following the presentation. About Merrimack Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development. Forward-looking statements Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
CONTACT: Investor Contact: Geoffrey M. Grande, Merrimack 617-441-7602 firstname.lastname@example.org Media Contact: Heather Gitlitz, Spectrum 202-955-6222 email@example.com